B
Beth A. Pangallo
Researcher at Eli Lilly and Company
Publications - 18
Citations - 749
Beth A. Pangallo is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Duloxetine & Placebo. The author has an hindex of 12, co-authored 18 publications receiving 625 citations.
Papers
More filters
Journal ArticleDOI
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Désirée van der Heijde,James Cheng-Chung Wei,Maxime Dougados,Philip J. Mease,Atul Deodhar,Walter P. Maksymowych,Filip Van den Bosch,Joachim Sieper,Tetsuya Tomita,Robert Landewé,Fangyi Zhao,Eswar Krishnan,David H. Adams,Beth A. Pangallo,Hilde Carlier,Melvin Churchill,Kathleen P. Flint,Geoffrey Gladstein,Maria Greenwald,Mary P. Howell,Akgun Ince,Jeffrey L. Kaine,Daksha Mehta,Eric A. Peters,Roel Querubin,John D. Reveille,Richard Roseff,Roger J. Diegel,Christine Thai,Louis Bessette,Frederic Morin,Proton Rahman,Aaron Alejandro Barrera Rodriguez,Fidencio Cons-Molina,Sergio Duran Barragan,Cassandra M. Skinner,Cesar Francisco Pacheco Tena,Cesar Ricardo Ramos Remus,Juan Cruz Rizo Rodriguez,Seung-Jae Hong,Yeon-Ah Lee,Ji Hyeon Ju,Seong Wook Kang,Tae-Hwan Kim,Chang Keun Lee,Eun Bong Lee,Sang-Heon Lee,Min Chan Park,Kichul Shin,Sang-Hoon Lee,Hung-An Chen,Ying-Chou Chen,Song-Chou Hsieh,Joung-Liang Lan,Zdenek Dvorak,Radka Moravcova,Martina Malcova,Yoshinori Taniguchi,Mitsumasa Kishimoto,Kurisu Tada,Hiroaki Dobashi,Kentaro Inui,Yukitaka Ueki,Yoshifuji Matsumoto,Yoshinobu Koyama,Kazuhiro Hatta,Tatsuya Atsumi,Hitoshi Goto,Kiyoshi Matsui,Yuya Takakubo,Gunther Neeck,Denis Poddubnyy,Andrea Rubbert-Roth,Malgorzata Szymanska,Tomasz Blicharski,Anna Dudek,Artur Racewicz,Rafal Wojciechowski,Marleen G H van de Sande,Ed Griep,Michael T. Nurmohamed,Galina Matsievskaya,Evgeniya Shmidt,Marina Stanislav,Sergey Yakushin,Olga Ershova,A P Rebrov,Tibor Balazs,Regina Cseuz,E. Drescher,Gyula Poor +90 more
TL;DR: Each dosing regimen of ixekizumab was superior to placebo for improving radiographic axial spondyloarthritis signs and symptoms in patients not previously treated with bDMARDs; the safety profile was consistent with previous indications of IXekzumab.
Journal ArticleDOI
Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine.
Michael E. Thase,Pierre V. Tran,Curtis Wiltse,Beth A. Pangallo,Craig H. Mallinckrodt,Michael J. Detke +5 more
TL;DR: The cardiovascular effects of duloxetine appear to be comparable with medications considered to be first-line options for depression, and no clinically meaningful effect on electrocardiogram profiles in a relatively healthy cohort of clinical trial patients.
Journal ArticleDOI
A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
TL;DR: Trial results were inconclusive, as neither the investigational drug (duloxetine) nor the active control (fluoxettine) separated from placebo on the CDRS-R at 10 weeks.
Journal ArticleDOI
A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder
Jeffrey R. Strawn,Apurva Prakash,Qi Zhang,Beth A. Pangallo,Chad Stroud,Na Cai,Robert L. Findling +6 more
TL;DR: Duloxetine was superior to placebo on the primary efficacy analysis of mean change from baseline to week 10 on the PARS severity for GAD score, and safety results were consistent with the known safety profile of duloxETine in pediatric and adult patients.
Journal ArticleDOI
Effects of the Antidepressant Duloxetine on Body Weight: Analyses of 10 Clinical Studies
TL;DR: In this paper, the effect of duloxetine, an inhibitor of serotonin and norepinephrine reup-take, on body weight of patients with major depressive disorder (MDD) was assessed.